Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp alfa + apatinib + short-course neoadjuvant chemoradiotherapy in resectable locally advanced rectal cancer
ChiCTR2600130635Phase 4Not yet recruiting
- Sponsor
- Quanzhou First Hospital
- Start
- Aug 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of retlirafusp alfa in rectal cancer, sponsored by Quanzhou First Hospital. Primary endpoint: complete remission rate (CR). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2600130635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130635.